paracetamol + ibuprofen (AFT Pharmaceuticals)

Maxigesic IV Paediatric is an intravenous fixed-dose combination of paracetamol (acetaminophen) and ibuprofen, specifically developed for the management of acute pain in the paediatric population. Developed by AFT Pharmaceuticals in collaboration with Hyloris Pharmaceuticals, the drug leverages the synergistic analgesic effects of its two components to provide superior pain relief compared to either agent alone. Ibuprofen acts as a non-selective inhibitor of cyclooxygenase enzymes (COX-1 and COX-2), thereby reducing the synthesis of pro-inflammatory prostaglandins. Paracetamol provides additional analgesic and antipyretic effects, likely through central nervous system mechanisms including the inhibition of prostaglandin synthesis and modulation of descending inhibitory pain pathways. The paediatric IV formulation is intended to address the need for effective post-operative pain management in hospital settings where oral administration is not feasible and aims to reduce the requirement for opioid analgesics.

Brand names

Maxigesic IV PaediatricCombogesic IV Paediatric

Other names

Paediatric paracetamol plus ibuprofen IVparacetamol + ibuprofen IVacetaminophen + ibuprofen IV